In a meta-analysis of 8 observational studies (4516 patients with chronic urticaria), median omalizumab drug survival was 3.1 years; early stopping was mainly for well-controlled disease, rarely adverse events. Autoimmune comorbidity was linked to stopping for lack of efficacy.
Meta-analysisn = 4,516
Altayf et al. Drug Survival of Omalizumab and Factors Associated With Discontinuation in Chronic Urticaria: A Meta-Analysis